Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs DrMedHealth

Claya
Graded #264

Lower grade

vs+3.4000000000000057
DrMedHealth
Graded #195

Higher grade

The verdict

DrMedHealth takes it — 66.2/100 to 62.8/100.

DrMedHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. DrMedHealth is a LegitScript-certified US telehealth platform for GLP-1 medical weight loss.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDrMedHealth +12
42
54
Dose & formulationDrMedHealth +2
75
77
Clinical oversightEven
82
82
Labs & monitoringEven
53
53
FulfillmentDrMedHealth +4
67
71
Contract termsClaya +6
61
55
Claya · left barDrMedHealth · right bar

The numbers

MetricClayaDrMedHealth
WeighScore62.8/10066.2/100
GradeCC
Scorecard rank#264#195
Semaglutide$299/mo (compounded)$199/mo (starting dose, compounded)
Tirzepatide$299/mo (compounded)$299/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Claya

Graded #264 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
DrMedHealth

Graded #195 · C

Strengths

  • LegitScript certified telehealth platform
  • Low compounded pricing: semaglutide from $199/mo, tirzepatide from $299/mo
  • Both compounded and FDA-approved branded options available
  • Fast physician review (advertised ~2 hours) with free shipping
  • Compounded by licensed US pharmacies

Where it loses points

  • Compounded GLP-1s are not FDA-approved for safety, efficacy or quality
  • Cash-pay model; insurance generally not accepted for medication
  • Full list of available states not consolidated in one place
  • Site is JavaScript-rendered, limiting easy review of full terms

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard